Semaglutide review finds fewer major cardiovascular events in chronic kidney disease
Randomized trials also favored semaglutide for kidney-related events, but evidence in people without diabetes still needs confirmation.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
In randomized trials of adults with chronic kidney disease, semaglutide lowered the combined risk of cardiovascular death, nonfatal heart attack or nonfatal stroke compared with placebo or standard care. Kidney-related events and cardiovascular deaths also favored semaglutide. The authors caution that findings in people without diabetes need further confirmation.
Follow-up lengths, absolute event rates and adverse-event counts are missing. The abstract's favorable safety conclusion cannot be independently assessed from its reported results.
What researchers found
Cardiovascular death, nonfatal heart attack or nonfatal stroke, combined
The combined event risk with semaglutide was 0.78 times that with placebo or standard care: a relative comparison. Absolute risks and follow-up length were not reported.
What the abstract covers
Researchers pooled randomized trials comparing semaglutide with placebo or usual care in adults with chronic kidney disease. This abstract-based summary focuses on reported cardiovascular and kidney outcomes, including deaths.
Reading a combined endpoint
A combined endpoint counts several different events together. Its lower risk does not establish equal benefit for each component; the abstract provides no separate estimates for nonfatal heart attack or stroke.
The original publication
Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Abdullah A, Sagreeka FNU, Aniket GA et al.
Endocrinol Diabetes Metab · 2025
- PubMed ID
- 41276951
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.